Moderate Fever Cycles as a Potential Mechanism to Protect the Respiratory System in COVID-19 Patients.
Fiche du document
2020
- doi: 10.3389/fmed.2020.564170
- issn: 2296-858X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3389/fmed.2020.564170
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33043037
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2296-858X
Ce document est lié à :
info:eu-repo/grantAgreement/SNF/////
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D318FD13ECFC1
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Mots-clés
COVID-19; Hsp70; SARS-CoV-2; acute respiratory distress syndrome; fever; heat- shock responseSujets proches
Hyperthermia PyrexiaCiter ce document
A. Guihur et al., « Moderate Fever Cycles as a Potential Mechanism to Protect the Respiratory System in COVID-19 Patients. », Serveur académique Lausannois, ID : 10.3389/fmed.2020.564170
Métriques
Partage / Export
Résumé
Mortality in COVID-19 patients predominantly results from an acute respiratory distress syndrome (ARDS), in which lungs alveolar cells undergo programmed cell death. Mortality in a sepsis-induced ARDS rat model is reduced by adenovirus over-expression of the HSP70 chaperone. A natural rise of body temperature during mild fever can naturally accumulate high cellular levels of HSP70 that can arrest apoptosis and protect alveolar lung cells from inflammatory damages. However, beyond 1-2 h of fever, no HSP70 is being further produced and a decreased in body temperature required to the restore cell's ability to produce more HSP70 in a subsequent fever cycle. We suggest that antipyretics may be beneficial in COVID-19 patients subsequent to several hours of mild (